Relative frequency and morphology of cancers in carriers of germline TP53 mutations
- PMID: 11498785
- DOI: 10.1038/sj.onc.1204621
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
Abstract
The spectrum and frequency of cancers associated with germline TP53 mutations are uncertain. To address this issue a cohort of individuals from 28 families with Li-Fraumeni syndrome, segregating germline TP53 mutations was established. Predicted cancers were estimated by applying age, morphology, site and sex-specific UK cancer statistics to person-years at risk. Observed and predicted cancers were compared and two-sided P-values calculated. Cancer types occurring to excess and showing P-values <0.02, were designated strongly associated with germline TP53 mutations. These were removed from the data and a second round of analyses performed. Cancer types with P-values <0.02 and 0.02-0.05 in the second round analyses were considered moderately and weakly associated respectively. Strongly associated cancers were: breast carcinoma, soft tissue sarcomas, osteosarcoma, brain tumours, adrenocortical carcinoma, Wilms' tumour and phyllodes tumour. Carcinoma of pancreas was moderately associated. Leukaemia and neuroblastoma were weakly associated. Other common carcinomas including lung, colon, bladder, prostate, cervix and ovary did not occur to excess. Although breast carcinoma and sarcomas were numerically most frequent, the greatest increases relative to general population rates were in adrenocortical carcinoma and phyllodes tumour. We conclude that germline TP53 mutations do not simply increase general cancer risk. There are tissue-specific effects.
Similar articles
-
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429. J Med Genet. 2010. PMID: 20522432
-
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.Oncogene. 1998 Sep 3;17(9):1061-8. doi: 10.1038/sj.onc.1202033. Oncogene. 1998. PMID: 9764816
-
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.Cancer Lett. 2007 Jan 8;245(1-2):96-102. doi: 10.1016/j.canlet.2005.12.039. Epub 2006 Feb 21. Cancer Lett. 2007. PMID: 16494995
-
[Germline mutations of the p53 gene].Pathol Biol (Paris). 1997 Dec;45(10):845-51. Pathol Biol (Paris). 1997. PMID: 9769948 Review. French.
-
[Li-Fraumeni syndrome].Bull Cancer. 1997 Jul;84(7):735-40. Bull Cancer. 1997. PMID: 9339200 Review. French.
Cited by
-
TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.BMC Cancer. 2013 Apr 9;13:187. doi: 10.1186/1471-2407-13-187. BMC Cancer. 2013. PMID: 23570263 Free PMC article.
-
Giant Benign Mammary Phyllodes Tumor: Report of a Case and Review of the Literature.Case Rep Oncol. 2021 Mar 1;14(1):123-133. doi: 10.1159/000510741. eCollection 2021 Jan-Apr. Case Rep Oncol. 2021. PMID: 33776693 Free PMC article. Review.
-
Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises.Curr Neurol Neurosci Rep. 2012 Apr;12(2):153-64. doi: 10.1007/s11910-011-0244-5. Curr Neurol Neurosci Rep. 2012. PMID: 22205236
-
Tumor suppression by p53: making cells senescent.Histol Histopathol. 2010 Apr;25(4):515-26. doi: 10.14670/HH-25.515. Histol Histopathol. 2010. PMID: 20183804 Free PMC article. Review.
-
The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.PLoS One. 2010 Dec 30;5(12):e15755. doi: 10.1371/journal.pone.0015755. PLoS One. 2010. PMID: 21209895 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous